249 filings
Page 2 of 13
8-K
i9zi1 j734
5 Jun 14
Material Modifications to Rights of Security Holders
12:00am
8-K
ko833ewq5
30 May 14
DARA BioSciences, Inc. Announces Pricing of $12.5 Million Public Offering
12:00am
8-K
vzhzajjcc ax
20 May 14
Submission of Matters to a Vote of Security Holders
12:00am
8-K
4x6bcayw68v4alky
12 May 14
Dara Biosciences Announces First Quarter 2014 Results
12:00am
8-K
0ponv5o6
25 Feb 14
Regulation FD Disclosure
12:00am
8-K
vnsyq
25 Feb 14
DARA BioSciences’ KRN5500 Receives Orphan Drug Designation from FDA
12:00am
8-K
vhbukhm9iob5
12 Feb 14
DARA BioSciences Announces Registered Direct Offering of $6.0 million
12:00am
8-K
9sgcsywu 7f
10 Feb 14
Regulation FD Disclosure
12:00am
8-K
dm58trbtzw
6 Feb 14
DARA BioSciences Announces 1-for-5 Reverse Split
12:00am
8-K
lm6dzj3fuha73
4 Feb 14
Dara Reports 2013 Fourth Quarter and Full Year Financial Results and Commercial Business Update
12:00am
8-K
yjksiaji jr
14 Nov 13
Dara Reports Third Quarter 2013 Financial Results and Highlights
12:00am
8-K
fubon
12 Nov 13
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
12:00am
8-K
04c3k7lty8ew35k2i
29 Oct 13
Departure of Directors or Certain Officers
12:00am
8-K
0u4m 4k0rzxiof
29 Oct 13
Regulation FD Disclosure
12:00am
8-K
guawh0r4i e5z7m7gvic
28 Oct 13
DARA BioSciences Announces Sales Force Expansion and Agreement with Mission Pharmacal in the Oncology Market
12:00am
8-K
7q58x toi
22 Oct 13
DARA BioSciences Announces Registered Direct Offering of $2.55 million
12:00am
8-K
8w2hbs1e8 vz9z5qjw
19 Aug 13
Dara Biosciences Announces At-the-market Common Stock
12:00am
8-K
no3g530un7w8qb69g5
14 Aug 13
Dara Reports Second Quarter 2013 Financial Results and Operational Overview
12:00am
8-K
4ki33e5xwryymk48c
18 Jun 13
DARA BioSciences Grants T3D Therapeutics Exclusive Worldwide Rights to Develop and Commercialize DB959
12:00am
8-K
pb0y0236
14 May 13
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
12:00am